Vitamin D and Inflammatory Markers of Cardiovascular Disease in African Americans With Type 2 Diabetes
NCT ID: NCT01153243
Last Updated: 2011-04-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
117 participants
INTERVENTIONAL
2007-04-30
2011-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vitamin D, C-reactive Protein and Insulin Resistance
NCT01019642
Vitamin D, Cardiovascular Disease, and African Americans
NCT01655810
Periodontal and Cardiometabolic Responses to Vitamin D Intervention in African Americans With Periodontal Disease
NCT02337257
Impact of Vitamin D on Diabetic Kidney Disease in African Americans
NCT01214356
Vitamin D and Type 2 Diabetes Study
NCT01942694
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Prevalence of vitamin D deficiency?
2. Correlation/relationship between vitamin D levels, Calcium level, parathyroid hormone (PTH) and Inflammatory markers
Setting: All visits will take place at the Fantus Diabetes Clinic.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ergocalciferol
The investigators will give intervention group 12 weeks of Vitamin D (ergocalciferol 50,000 units every week)
Ergocalciferol
Active Comparator: Ergocalciferol
The investigators will give intervention group 12 weeks of Vitamin D (ergocalciferol 50,000 units every week)
Placebo pill
The investigators will give intervention group 12 weeks of placebo pill (in pill every week)
Placebo pill
The investigators will give control group 12 weeks of 1 placebo pill every week.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ergocalciferol
Active Comparator: Ergocalciferol
The investigators will give intervention group 12 weeks of Vitamin D (ergocalciferol 50,000 units every week)
Placebo pill
The investigators will give control group 12 weeks of 1 placebo pill every week.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* DM type 2
Exclusion Criteria
* hypocalcemia
* hypercalcemia
* malabsorption
* liver disease
* patients with creatinine \> 1.5. (CKD \>/= 3)
* pregnancy
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rush University
OTHER
Cook County Health
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
John H Stroger Hospital of Cook County
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Leon Fogelfeld, MD
Role: STUDY_DIRECTOR
Cook County Health
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
#07-061
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.